Clinical trials: Psychotic Disorder
Schizophrenia
Transcranial Direct Current Stimulation (TDCS) for Auditory Hallucinations in Early Onset Schizophrenia (EOS)
Youths diagnosed with early onset schizophrenia will demonstrate amelioration of auditory hallucinations after one week of twice daily treatment with transcranial direct current stimulation (tDCS).
- Trial name
- NCT02764164
- Testing
- Intervention Active tDCS
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Schizophrenia
A Study To Examine Safety, Pharmacokinetics, And Pharmacodynamic Of Pf 06412562 In Subjects With Schizophrenia
This study is designed to investigate the safety, tolerability pharmacokinetics and pharmacodynamic effects of PF-06412562 following multiple dose administration as MR tablets in subjects with schizophrenia.
- Trial name
- NCT02418819
- Testing
- PF-06412562 3mg BID, PF-06412562 9mg BID, PF-06412562 45mg BID
- Where
- 6 sites in United States
- Volunteers
- 103 people
- Sponsor
- Pfizer
Schizophrenia
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
The purpose of this study is to evaluate the efficacy of the drug SM-13496 compared to a placebo and to haloperidol in patients with schizophrenia.
- Trial name
- NCT00044044
- Testing
- Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg
- Where
- 34 sites in United States
- Volunteers
- 356 people
- Sponsor
- Sumitomo Pharma America, Inc.
Schizophrenia, Schizoaffective Disorder
Schizophrenic Patients in Integrated Care
The purpose of the study is to investigate the well-being of schizophrenic patients treated with quetiapine XR combined with participation in the integrated care program compared to a treatment with quetiapine XR alone over a…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Trial name
- CARE II (NCT00681629)
- Testing
- Quetiapine XR, Integrated Care Program (ICP)
- Where
- 8 sites in Germany
- Volunteers
- 7 people
- Sponsor
- AstraZeneca
Acute Schizophrenia, Schizoaffective Disorder
RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder
The objective of this study is to evaluate the efficacy and safety of RP5063 relative to placebo for the treatment of schizophrenia or schizoaffective disorder.
- Trial name
- REFRESH (NCT01490086)
- Testing
- RP5063, aripiprazole
- Where
- 15 sites in United States, India and 3 more
- Volunteers
- 234 people
- Sponsor
- Reviva Pharmaceuticals
Schizophrenia
A 4-week, Randomized, Rater-blinded, Parallel Study to Evaluate Quetiapine in Improving Sleep Quality of Schizophrenia
This study will apply polysomnography (PSG) to evaluate the effect of quetiapine fumarate on sleep architecture. Most of previous studies evaluated sleep by self-reported questionnaires during the antipsychotic treatment…
- Trial name
- NCT00642369
- Testing
- quetiapine fumarate, haloperidol
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Guang Dong Provincial Mental Health Institute
Psychotic Disorders, Psychosis Nos/Other
Psychosis Screening in Juvenile Justice
This study will investigate the occurrence of psychosis-spectrum disorders among youth in the Juvenile Justice System and track mental health referrals for these youth in Phase 1, a standard care condition.
- Trial name
- JJ-Psychosis (NCT03583073)
- Testing
- Enhanced Referral/Linkage to Care, Standard Care
- Where
- 2 sites in United States
- Volunteers
- 77 people
- Sponsor
- Brown University
Schizophrenia
Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
The study evaluates the efficacy and safety of SM-13496 compared with placebo in patients with schizophrenia.
- Trial name
- NCT00711269
- Testing
- SM-13496 (lurasidone HCl), Risperidone
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 460 people
- Sponsor
- Sumitomo Pharma Co., Ltd.
Parenting, Adolescent - Emotional Problem
Optimizing Residential Treatment Gains for Adolescents
The goal of this randomized controlled trial is to determine the feasibility, acceptability, and preliminary effects of a web-based parent training augmented with facilitated parent groups.
- Conditions
- Parenting, Adolescent - Emotional Problem, Mental Disorder in Adolescence
- Trial name
- NCT05764369
- Testing
- Parenting Wisely Residential Treatment (PWRT), TAU
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Ohio State University
Schizophrenia
A Pharmacokinetic and Safety Study of Paliperidone Palmitate (JNS010) in Participants With Schizophrenia
The purpose of this study is to assess the pharmacokinetics (the study of the way a drug enters and leaves the blood and tissues over time) and safety of paliperidone palmitate in participants with schizophrenia (psychiatric…
- Trial name
- NCT01606254
- Testing
- Paliperidone palmitate
- Where
- Japan
- Volunteers
- 56 people
- Sponsor
- Janssen Pharmaceutical K.K.
Antipsychotic-induced Weight Gain (AIWG)
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Miricorilant (CORT118335) in Obese Adults With Schizophrenia or Bipolar Disorder Treated With Antipsychotic Medications
This phase 2, double blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with…
- Trial name
- GRATITUDE (NCT03818256)
- Testing
- Miricorilant
- Where
- 27 sites in United States
- Volunteers
- 71 people
- Sponsor
- Corcept Therapeutics
Schizophrenia, Schizophreniform Disorders
Horyzons: Implementation and Integration in Clinical Practice
The primary aim of this trial is evaluating the barriers and enablers of implementing a digital intervention with both therapeutic content and social networking, Horyzons, as part of clinical care in first episode psychosis (FEP)…
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Unspecified or Other Psychotic Disorders
- Trial name
- NCT06002958
- Testing
- Horyzons USA
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- University of North Carolina, Chapel Hill
Epilepsy, Schizophrenia
Targeted Self-Management for Epilepsy and Serious Mental Illness (TIME)
For this project we propose to refine the psychosocial intervention developed in phase one, based on input from key stakeholders, and to test the feasibility, acceptability and preliminary efficacy of the intervention.
- Conditions
- Epilepsy, Schizophrenia, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01992393
- Testing
- TIME
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Western Reserve University
Schizoaffective Disorder, Schizophrenia
Long-Acting Injectable Risperidone in the Treatment of Schizophrenia
In the proposed study 450 veterans with a primary diagnosis of schizophrenia who had at least one psychiatric hospitalization for schizophrenia in the previous 2 years would be randomly assigned at 16 VA medical centers to…
- Trial name
- NCT00132314
- Testing
- IM risperidone, oral antipsychotic medication
- Where
- 19 sites in United States
- Volunteers
- 382 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Trial to Evaluate the Short-term Safety & Efficacy of Brexpiprazole Monotherapy in the Treatment of Adolescents With Schizophrenia
To determine the safety \& efficacy of brexpiprazole monotherapy in the treatment of adolescents with schizophrenia.
- Trial name
- NCT03198078
- Testing
- Brexpiprazole (OPC-34712), Aripiprazole
- Where
- United States
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia
The objective of this study is to test a single dose of intranasal oxytocin, compared to placebo, in a within subjects, crossover design, to see if oxytocin will improve satiety signaling (behaviorally and/or by self report)…
- Trial name
- NCT01614093
- Testing
- Oxytocin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Maryland, Baltimore
Tobacco Dependence, Schizophrenia
Cigarette Smoking in Smokers With and Without Schizophrenia
Higher rates and severity of tobacco dependence in people with schizophrenia, as compared with the general population, contribute to the lower life expectancy seen in this population.
- Trial name
- NCT04001114
- Testing
- Sampling Research Cigarettes
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia
To evaluate the safety and tolerability of multiple doses of PF 02545920 administered orally to psychiatrically stable subjects with schizophrenia receiving background antipsychotic +/- other adjunctive medication.
- Trial name
- NCT01829048
- Testing
- PF-02545920
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Pfizer
Schizophrenia
Trial of D-Cycloserine in Schizophrenia
To characterize further the effects of D-cycloserine augmentation of antipsychotic treatment on negative symptoms, performance on neurocognitive tasks, and on markers for glutamatergic, dopaminergic and serotonergic function in…
- Trial name
- NCT00000371
- Testing
- D-cycloserine
- Volunteers
- 60 people
- Sponsor
- Massachusetts General Hospital
Suicide, Psychosis
Cognitive Behavioral Suicide Prevention for Psychosis: Aim 1
The investigators are modifying and testing the preliminary effectiveness and implementation of a Cognitive Behavioral Suicide Prevention for psychosis (CBSPp) intervention.
- Trial name
- NCT04689867
- Testing
- Cognitive Behavioral Suicide Prevention for psychosis CBSPp)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Michigan